Inclusion Criteria:~* Subject has completed the Week 26 visit of either of the two blinded parent studies
(ATH-1017-AD-0201 or ATH-1017-AD-0202).~* Reliable and capable support person/caregiver who is willing to
accept responsibility for supervising the daily treatment or, if required, administering study drug.~* Subject
capable of giving signed informed consent, or by a legally acceptable representative.~* Subjects must be in
generally good health.~* Male subjects and their partners must agree to continue to use a double-barrier method
of contraception during the study, including the follow-up period, unless the partner is not of childbearing
potential.~
